IncobotulinumtoxinA (Xeomin) Injections For Cervical Dystonia: A Repeated-Dose Study

re ductions in the International Restless Legs Syndrome Rating Scale sum scores by 2.09 to 2.55 points compared with a re-duction of 1.34 points for the placebo patients. Quality of life was also improved with rotigotine, Dr. Kohnen said. At baseline, 60 % of subjects rated themselves as being moderately to extremely impaired because of pain. In this subgroup, after 6 months of treatment, the mean change in RLS–QOL for item 8 in the rotigotine groups was significantly greater than that observed with placebo (P < 0.01). Among rotigotine-treated patients, 60 % reported improvement of at least 2 points compared with 44 % in the placebo group. Among the rotigotine group, one-third no longer reported impairment from pain compared with 19 % in the placebo group. “Rotigotine works in restless legs syndrome, ” Dr. Kohnen concluded, “and those who have pain and resulting mood problems can expect that these symptoms will decrease or dis-appear.” The Neupro patch is currently available in Europe but was removed from the U.S. market in 2008 because of a formula-tion problem. The patch is expected to be approved in the U.S. again in 2012.